Abstract
Purpose
The folate receptor (FR) is a valuable tumour marker, since it is frequently overexpressed on various cancer types. The purpose of the present study was to pre-clinically evaluate novel site-specifically modified 99mTc(CO)3 folate (γ-derivative 4, α-derivative 5) and pteroate (6) conjugates for FR targeting.
Methods
The 99mTc(CO)3 radiotracers 4–6 were prepared by a kit-like procedure. In vitro characterisation (K D and B max) of the radiotracers was performed with FR-positive KB cells. Tissue distribution was studied in tumour-bearing mice. SPECT/CT experiments were performed with a dedicated small animal SPECT/CT scanner.
Results
The complexes 4–6 were formed in high yields (>92%). Binding constants of the radiotracers (K D in nM: 4: 2.09; 5: 2.51; 6: 14.52) were similar to those of 3H-folic acid (K D in nM: 7.22). In vivo the folate derivatives showed significantly better tumour uptake (4: 2.3±0.4% ID/g and 5: 1.2±0.2% ID/g, 4 h p.i.) than the pteroate derivative (6: 0.4±0.2% ID/g, 4 h p.i.). Clearance of all radiotracers from the blood pool and from non-targeted tissues was efficient (tumour to blood ratio approx. 200–350, 24 h p.i.). FR-positive tissue and organs were successfully visualised via small animal SPECT/CT.
Conclusion
Radiotracers 4–6 are the first 99mTc(CO)3 tracers prepared via a kit formulation which exhibit full biological activity in vitro and in vivo. Folate derivatives 4 and 5 revealed significantly better pharmacokinetic properties than the pteroate derivative 6. Promising pre-clinical SPECT results warrant further assessment of 99mTc(CO)3 radiofolates for detection of FR-positive tumours.
Similar content being viewed by others
References
Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297–303
Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991;51:6125–6132
Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396–3401
Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193–198
Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284–293
Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001;6:44–51
Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147–162
Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004;56:1127–1141
Li S, Deshmukh HM, Huang L. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res 1998;15:1540–1545
Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells—contribution of translocation domain. J Biol Chem 1993;268:24847–24854
Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004;56:1177–1192
Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, et al. Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol 2003;30:725–731
Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J Nucl Med 1996;37:1003–1008
Mathias CJ, Wang S, Low PS, Waters DJ, Green MA. Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts. Nucl Med Biol 1999;26:23–25
Ke CY, Mathias CJ, Green MA. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol 2003;30:811–817
Guo WJ, Hinkle GH, Lee RJ. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 1999;40:1563–1569
Mathias CJ, Green MA. A kit formulation for preparation of [111In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol 1998;25:585–587
Mathias CJ, Green MA. Alternative kit formulations for compounding of 111In-DTPA-folate (folatescan). J Nucl Med 2000;41:1113
Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700–707
Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, et al. Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjugate Chem 2002;13:1200–1210
Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45:857–866
Alberto R. New organometallic technetium complexes for radiopharmaceutical imaging. In: Krause W, editor. Contrast agents III: Radiopharmaceuticals—from diagnostics to therapeutics. Berlin Heidelberg New York: Springer; 2005; p. 1–44
Boschi A, Duatti A, Uccelli L. Development of technetium-99m and rhenium-188 radiopharmaceuticals containing a terminal metal-nitrido multiple bond for diagnosis and therapy. In: Krause W, editor. Contrast agents III: Radiopharmaceuticals—from diagnostics to therapeutics. Berlin Heidelberg New York: Springer; 2005; p. 85–115
Alberto R, Schibli R, Egli A, Schubiger AP, Abram U, Kaden TA. A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [99mTc(OH2)3(CO)3]+from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 1998;120:7987–7988
Alberto R, Schibli R, Waibel R, Abram U, Schubiger AP. Basic aqueous chemistry of [M(OH2)3(CO)3]+(M=Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev 1999;192:901–919
Schibli R, La Bella R, Alberto R, Garcia-Garayoa E, Ortner K, Abram U, et al. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjugate Chem 2000;11:345–351
Alberto R, Ortner K, Wheatley N, Schibli R, Schubiger AP. Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [99mTc(OH2)3(CO)3]+. J Am Chem Soc 2001;123:3135–3136
Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2002;29:1529–1542
Müller C, Dumas C, Hoffmann U, Schubiger PA, Schibli R. Organometallic 99mTc-technetium(I)- and Re-rhenium(I)-folate derivatives for potential use in nuclear medicine. J Organomet Chem 2004;689:4712–4721
Antony AC, Kane MA, Portillo RM, Elwood PC, Kolhouse JF. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem 1985;260:4911–4917
Dixon KH, Mulligan T, Chung KN, Elwood PC, Cowan KH. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells. J Biol Chem 1992;267:24140–24147
Ladino CA, Chari RVJ, Bourret LA, Kedersha NL, Goldmacher VS. Folate-maytansinoids: target-selective drugs of low molecular weight. Int J Cancer 1997;73:859–864
Trump DP, Mathias CJ, Yang ZF, Low PSW, Marmion M, Green MA. Synthesis and evaluation of 99mTc(CO)3-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol 2002;29:569–573
Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: effect of alternative conjugation chemistry. J Drug Target 1999;7:157–169
Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RGW. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 1988;263:13602–13609
Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 2004;66:1406–1414
Spinella MJ, Brigle KE, Sierra EE, Goldman ID. Distinguishing between folate receptor-a-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 1995;270:7842–7849
Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci U S A 1986;83:5983–5987
Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56:1205–1217
Birn H, Spiegelstein O, Christensen EI, Finnell RH. Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol 2005;16:608–615
Morshed KM, Ross DM, McMartin KE. Folate transport proteins mediate the bidirectional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. J Nutr 1997;127:1137–1147
Selhub J, Rosenberg IH. Demonstration of high-affinity folate binding activity associated with brush border membranes of rat kidney. Proc Natl Acad Sci U S A 1978;75:3090–3093
Goresky CA, Watanabe H, Johns DG. Renal excretion of folic acid. J Clin Invest 1963;42:1841
Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS,Green MA. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med 1998;39:1579–1585
Mathias CJ, Hubers D, Low PS, Green MA. Synthesis of [99mTc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjugate Chem 2000;11:253–257
Ke CY, Mathias CJ, Green MA. Targeting the tumor-associated folate receptor with an 111In-DTPA conjugate of pteroic acid. J Am Chem Soc 2005;127:7421–7426
Acknowledgements
We thank Dr. Ilse Novak-Hofer, Dr. Robert Waibel and Dr. Elisa Garcia-Garayoa for valuable discussions and Alain Blanc, Judith Stahel and Christine De Pasquale for technical assistance. This work was financially supported by Mallinckrodt-Tyco Inc. and Merck Eprova AG.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Müller, C., Hohn, A., Schubiger, P.A. et al. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur J Nucl Med Mol Imaging 33, 1007–1016 (2006). https://doi.org/10.1007/s00259-006-0111-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-006-0111-9